TY - JOUR
T1 - Effects of prostaglandin E1 (PGE1) on pulmonary hypertension and lung vascular remodeling in a rat monocrotaline model of human pulmonary hypertension
AU - Ono, S.
AU - Tanita, T.
AU - Hoshikawa, Yasushi
AU - Song, C.
AU - Maeda, Sumiko
AU - Tabata, T.
AU - Noda, M.
AU - Ueda, S.
AU - Ashino, Yugo
AU - Fujimura, S.
PY - 1995/1/1
Y1 - 1995/1/1
N2 - Prostaglandin E1 (PGE1) has been shown to be a potent pulmonary vasodilator in humans and in many animals. The effects of PGE1 on the development of pulmonary hypertension and on pulmonary vascular remodeling were studied in a rat monocrotaline (MCT) model of human pulmonary hypertension. By 3 weeks after injection, MCT (80 mg/kg S.C.) had resulted in high values of mean pulmonary arterial pressure and of the ratio of right ventricular weight to left ventricle + septum weight (RV/LV + S). PGE1 inhibited the development of pulmonary hypertension (300 μg/kg) and right ventricular hypertrophy (300 and 100 μg/kg) induced by MCT. Three weeks after the injection, the media walls of pulmonary arteries in lungs from rats given MCT were significantly thicker than those from lungs of control rats. PGE, (300, 100, and 30 μg/kg) resulted in significantly less of this morphologic change, in a dose-dependent manner. These results indicate that PGE1 inhibits the development of pulmonary hypertension associated with lung vascular thickening induced by MCT. PGE1 may be useful for the treatment of pulmonary hypertension in humans.
AB - Prostaglandin E1 (PGE1) has been shown to be a potent pulmonary vasodilator in humans and in many animals. The effects of PGE1 on the development of pulmonary hypertension and on pulmonary vascular remodeling were studied in a rat monocrotaline (MCT) model of human pulmonary hypertension. By 3 weeks after injection, MCT (80 mg/kg S.C.) had resulted in high values of mean pulmonary arterial pressure and of the ratio of right ventricular weight to left ventricle + septum weight (RV/LV + S). PGE1 inhibited the development of pulmonary hypertension (300 μg/kg) and right ventricular hypertrophy (300 and 100 μg/kg) induced by MCT. Three weeks after the injection, the media walls of pulmonary arteries in lungs from rats given MCT were significantly thicker than those from lungs of control rats. PGE, (300, 100, and 30 μg/kg) resulted in significantly less of this morphologic change, in a dose-dependent manner. These results indicate that PGE1 inhibits the development of pulmonary hypertension associated with lung vascular thickening induced by MCT. PGE1 may be useful for the treatment of pulmonary hypertension in humans.
KW - Monocrotaline
KW - Prostaglandin E
KW - Pulmonary Hypertension
KW - Pulmonary vascular remodeling
KW - Right ventricular hypertrophy
UR - http://www.scopus.com/inward/record.url?scp=0029112840&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029112840&partnerID=8YFLogxK
M3 - Article
C2 - 7474567
AN - SCOPUS:0029112840
VL - 33
SP - 862
EP - 867
JO - Respiratory Investigation
JF - Respiratory Investigation
SN - 2212-5345
IS - 8
ER -